7569-62-2

Basic information

• Product Name: (5-CHLORO-2-METHOXYPHENYL)ACETIC ACID
• Synonyms: 2-(Carboxymethyl)-4-chloroanisole;5-chloro-2-methoxyBenzeneacetic acid
• CAS NO: 7569-62-2
• Molecular Formula: C₉H₉ClO₃
• Molecular Weight: 200.619
• Mol File: 7569-62-2.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 323.5°Cat760mmHg
• Flash Point: 149.4°C
• Appearance: /
• Density: 1.312g/cm³
• Vapor Pressure: 0.000107mmHg at 25°C
• Refractive Index: 1.553
• CAS DataBase Reference: (5-CHLORO-2-METHOXYPHENYL)ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (5-CHLORO-2-METHOXYPHENYL)ACETIC ACID(7569-62-2)
• EPA Substance Registry System: (5-CHLORO-2-METHOXYPHENYL)ACETIC ACID(7569-62-2)

Safety Data

• Hazardous Substances Data: 7569-62-2(Hazardous Substances Data)

Usage

General Description

(5-Chloro-2-methoxyphenyl)acetic acid, also known as lornoxicam, is a nonsteroidal anti-inflammatory drug (NSAID) that is used to reduce pain and inflammation in conditions such as rheumatoid arthritis and osteoarthritis. It works by inhibiting the production of prostaglandins, which are responsible for pain and inflammation. The chemical has analgesic, anti-pyretic, and anti-inflammatory properties, making it an effective medication for managing pain and inflammation. However, it is important to use this drug according to the prescribed dosage and under the guidance of a healthcare professional, as it may have potential side effects and interactions with other medications.

InChI:InChI=1/C9H9ClO3/c1-13-8-3-2-7(10)4-6(8)5-9(11)12/h2-4H,5H2,1H3,(H,11,12)

Upstream product

• 93-25-4 2-methoxyphenylacetic acid 
• 917107-30-3 2-(5-chloro-2-methoxy-phenyl)-1-morpholin-4-yl-ethanethione 
• 7035-11-2 4-chloro-2-chloromethyl-1-methoxy-benzene 
• 623-12-1 4-chloromethoxybenzene 
• 6342-64-9 2-methoxy-5-chloroacetophenone 
• 7048-38-6 (5-chloro-2-methoxy-phenyl)-acetonitrile 
• 26939-01-5 5-chloro-2-methoxyphenylacetic acid,methyl ester 

Downstream Products

• 1050481-78-1 ethyl 2-(5-chloro-2-methoxyphenyl)acetate 
• 917107-29-0 2-(5-chloro-2-hydroxyphenyl)-N-methylacetamide 
• 913650-07-4 2-[5-chloro-2-(methyloxy)phenyl]acetamide 
• 76322-41-3 ethyl (5-chloro-2-hydroxyphenyl)acetate 
• 26939-01-5 5-chloro-2-methoxyphenylacetic acid,methyl ester 
• 7569-67-7 N-Methyl-<2-methoxy-5-chlor>-β-phenaethylamin 
• 7569-66-6 N-Benzyl-<2-methoxy-5-chlor-phenyl>-acetamid 
• 7569-65-5 N-Aethyl-<2-methoxy-5-chlor-phenyl>-acetamid 
• 14613-38-8 <2-Methoxy-5-chlor-phenyl>-aethylbromid 
• 7593-00-2 <2-Methoxy-5-chlor-phenyl>-aethylchlorid 
• 76322-42-4 (5-Chloro-2-ethoxycarbonylmethoxy-phenyl)-acetic acid ethyl ester 
• 7569-69-9 (2-Methoxy-5-chlor-phenyl)-aethanol 
• 7569-63-3 (5-chloro-2-methoxyphenyl)acetyl chloride 
• 24161-38-4 5-chloro-2-hydroxyphenylacetic acid 

Relevant articles and documents

Efficient halogenation synthesis method of aryl halide

The invention discloses an efficient halogenation synthesis method of aryl halide. The method comprises the following step: in the presence of a catalyst (sulfoxide or oxynitride), a halogenation reagent and a solvent, carrying out a halogenation reaction on an aromatic ring compound to obtain the aryl halide. According to the present invention, in the presence of a catalyst (sulfoxide or nitrogenoxide), a halogenation reagent and a solvent, the aromatic ring is subjected to an efficient halogenation reaction, such that the very useful aryl halide can be obtained with high activity and high selectivity; and by adopting the method disclosed by the invention, aryl halides can be efficiently synthesized, and the method has a wide application prospect in actual production.

COMPOUNDS

Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R5b X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.

Piperazinyl CCR1 antagonists-optimization of human liver microsome stability

The synthesis, biological activity, and pharmacokinetic profile of CCR1 antagonists are described.